Petros Pharmaceuticals, Inc.
PTPI
$0.1268
$0.00736.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.11M | 4.02M | 4.12M | 4.69M | 5.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.11M | 4.02M | 4.12M | 4.69M | 5.82M |
| Cost of Revenue | 1.21M | 1.11M | 1.23M | 1.41M | 1.63M |
| Gross Profit | 3.90M | 2.92M | 2.89M | 3.28M | 4.19M |
| SG&A Expenses | 8.75M | 10.18M | 9.88M | 9.84M | 9.26M |
| Depreciation & Amortization | 2.83M | 2.98M | 3.07M | 3.17M | 3.28M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.41M | 17.61M | 17.32M | 18.07M | 16.58M |
| Operating Income | -10.30M | -13.59M | -13.20M | -13.38M | -10.76M |
| Income Before Tax | -14.32M | -4.73M | -7.06M | -8.94M | -8.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.32 | -4.73 | -7.06 | -8.94 | -8.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.32M | -4.73M | -7.06M | -8.94M | -8.16M |
| EBIT | -10.30M | -13.59M | -13.20M | -13.38M | -10.76M |
| EBITDA | -7.46M | -10.61M | -10.13M | -10.21M | -7.48M |
| EPS Basic | -91.47 | -105.16 | -163.08 | -183.89 | -158.29 |
| Normalized Basic EPS | -21.78 | -9.94 | -39.95 | -57.34 | -60.60 |
| EPS Diluted | -91.47 | -105.16 | -163.08 | -183.89 | -158.29 |
| Normalized Diluted EPS | -21.78 | -9.94 | -39.95 | -57.34 | -60.60 |
| Average Basic Shares Outstanding | 1.28M | 974.10K | 665.70K | 454.90K | 348.10K |
| Average Diluted Shares Outstanding | 1.28M | 974.10K | 665.70K | 454.90K | 348.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |